| scholarly article | Q13442814 |
| P50 | author | Filip Janku | Q73569186 |
| P2093 | author name string | Ahmed Kaseb | |
| Manojkumar Bupathi | |||
| P2860 | cites work | Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis | Q24313372 |
| Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma | Q24563486 | ||
| Molecular therapies in hepatocellular carcinoma: what can we target? | Q27025381 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Hepatocellular carcinoma | Q29615765 | ||
| The biology of vascular endothelial growth factor | Q29615946 | ||
| Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth | Q33732486 | ||
| Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway | Q33896998 | ||
| Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing | Q33917547 | ||
| Estimating the world cancer burden: Globocan 2000 | Q34518922 | ||
| Angiopoietin-2 is implicated in the regulation of tumor angiogenesis | Q35746320 | ||
| Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2 | Q36223383 | ||
| Pancreatic cancer: an update | Q36790158 | ||
| Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword? | Q37970070 | ||
| Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. | Q52534158 | ||
| Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs | Q53179408 | ||
| TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. | Q54496036 | ||
| Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma | Q54526554 | ||
| Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. | Q54597476 | ||
| Angiopoietin-2 Serum Levels Are Elevated in Patients With Liver Cirrhosis and Hepatocellular Carcinoma | Q58099091 | ||
| Expression of angiopoietin-2 gene and its receptor Tie2 in hepatocellular carcinoma | Q78828703 | ||
| Angiopoietin-2 impairs revascularization after limb ischemia | Q80412365 | ||
| mTOR as a Potential Target for the Prevention and Treatment of Hepatocellular Carcinoma | Q38032897 | ||
| Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy | Q38087230 | ||
| Antiangiogenic therapies: going beyond their limits | Q38172781 | ||
| Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? | Q38520141 | ||
| Angiotensin II Induces Angiogenic Factors Production Partly Via AT1/JAK2/STAT3/SOCS3 Signaling Pathway in MHCC97H Cells | Q39344956 | ||
| Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial | Q39653331 | ||
| Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology | Q39919528 | ||
| Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma | Q43933938 | ||
| Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors | Q44649604 | ||
| Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma | Q45339888 | ||
| Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. | Q45866300 | ||
| Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma | Q47741987 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 1927-32 | |
| P577 | publication date | 2014-01-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | OncoTargets and Therapy | Q7092081 |
| P1476 | title | Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives | |
| P478 | volume | 7 |
| Q28553513 | A Hybrid Chalcone Combining the Trimethoxyphenyl and Isatinyl Groups Targets Multiple Oncogenic Proteins and Pathways in Hepatocellular Carcinoma Cells |
| Q41574359 | A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy |
| Q36825943 | A double suicide gene system driven by vascular endothelial growth factor promoter selectively kills human hepatocellular carcinoma cells |
| Q61454351 | Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma |
| Q36313998 | From big data to diagnosis and prognosis: gene expression signatures in liver hepatocellular carcinoma |
| Q41446079 | Liposomal curcumin inhibits hypoxia-induced angiogenesis after transcatheter arterial embolization in VX2 rabbit liver tumors |
| Q60936609 | Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy |
| Q36121903 | Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis |
| Q38693339 | Serum biomarker analysis in patients with recurrent spontaneous abortion |
Search more.